Correlation Profile of Suppression of Tumorigenicity 2 and/or Interleukin-33 with Biomarkers in the Adipose Tissue of Individuals with Different Metabolic States
Amal Hasan,1 Shihab Kochumon,1 Ebaa Al-Ozairi,2,3 Jaakko Tuomilehto,4– 6 Fahd Al-Mulla,7 Rasheed Ahmad1 1Department of Immunology and Microbiology, Dasman Diabetes Institute, Kuwait City, Kuwait; 2Clinical Research Unit, Medical Division, Dasman Diabetes Institute, Kuwait City, Kuwait; 3De...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5941123870844132be86caad6455dd87 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Amal Hasan,1 Shihab Kochumon,1 Ebaa Al-Ozairi,2,3 Jaakko Tuomilehto,4– 6 Fahd Al-Mulla,7 Rasheed Ahmad1 1Department of Immunology and Microbiology, Dasman Diabetes Institute, Kuwait City, Kuwait; 2Clinical Research Unit, Medical Division, Dasman Diabetes Institute, Kuwait City, Kuwait; 3Department of Medicine, Faculty of Medicine, Kuwait City, Kuwait; 4Research Division, Dasman Diabetes Institute, Kuwait City, Kuwait; 5Department of Public Health, University of Helsinki, Helsinki, Finland; 6National School of Public Health, Madrid, Spain; 7Department of Genetics and Bioinformatics, Functional Genomics, Dasman Diabetes Institute, Kuwait City, KuwaitCorrespondence: Amal Hasan Email amal.hasan@dasmaninstitute.orgPurpose: The suppression of tumorigenicity 2 (ST2) has two main splice variants including a membrane bound (ST2) form, which activates the myeloid differentiation primary response 88 (MyD88)/nuclear factor-kappa B (NF-κB) signaling pathway, and a secreted soluble form (sST2), which acts as a decoy receptor for ST2 ligand, interleukin (IL)-33. The IL-33/ST2 axis is protective against obesity, insulin resistance, and type 2 diabetes (T2D). In humans, adipose tissue IL-33 displays distinct correlation profiles with glycated hemoglobin, ST2, and other immunometabolic mediators, depending on the glycemic health of the individuals. We determined whether adipose tissue ST2 displays distinct correlation profiles with immunometabolic mediators and whether ST2 and/or IL-33 are correlated with intracellular signaling molecules.Patients and Methods: A total of 91 adults with normal glycemia, prediabetes, and T2D were included. After measuring their anthropometric and biochemical parameters, subcutaneous adipose tissues were isolated and mRNA expression of biomarkers was measured.Results: In individuals with normal glycemia, adipose tissue ST2 was directly correlated with chemokine (C-C motif) ligand (CCL)-2, CCL5, IL-12, fibrinogen-like protein 2 (FGL2) and interferon regulatory factor (IRF)-4, but inversely correlated with cytochrome C oxidase subunit 7A1. IL-33 and ST2 were directly correlated with tumor necrosis factor receptor-associated factor 6 (TRAF6), NF-κB, and nuclear factor of activated T-cells 5 (NFAT5). In individuals with prediabetes, ST2 was inversely correlated with IL-5, whereas IL-33 but not ST2 was directly correlated with MyD88 and NF-κB. In individuals with T2D, ST2 was directly correlated with CCL2, IL-1β, and IRF5. IL-33 and ST2 were directly correlated with MyD88, TRAF6, and NF-κB.Conclusion: Adipose tissue ST2 and IL-33 show different correlation profiles with various immunometabolic biomarkers depending on the metabolic state of the individuals. Therefore, targeting the IL-33/ST2 axis might form the basis for novel therapies to combat metabolic disorders.Keywords: obesity, prediabetes, type 2 diabetes, suppression of tumorigenicity 2, interleukin-33 |
|---|